Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03285321 · ClinicalTrials.gov registry record · Phase 2
Unresectable Stage IIIA/IIIB Non-small Cell Lung Cancer (NSCLC)
A Phase 2 study, sponsored by Greg Durm, MD.
- Completed
- Registry status
- Phase 2
- Development phase
- 105
- Enrollment target
NCT03285321 is a Phase 2 study that has completed, run by Greg Durm, MD. The registered enrollment target is 105 participants.
The verdict
NCT03285321, a Phase 2 study, has completed, sponsored by Greg Durm, MD.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 105 participants
- Enrollment target
Study Summary
This study is an open label, multicenter, randomized phase II trial of consolidation immunotherapy with either nivolumab alone or the combination of nivolumab and ipilimumab following concurrent chemoradiation in patients with unresectable stage III NSCLC.
Interventions
- DRUG Nivolumab
- DRUG Ipilimumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 105 participants |
| Start Date | 2017-09-15 |
| Est. Completion | 2024-02-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03285321
The ClinicalTrials.gov registry entry for NCT03285321 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 105 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Greg Durm, MD, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Nivolumab is the first listed.
NCT03285321 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03285321 about?
NCT03285321 is a clinical study titled "Unresectable Stage IIIA/IIIB Non-small Cell Lung Cancer (NSCLC)". This study is an open label, multicenter, randomized phase II trial of consolidation immunotherapy with either nivolumab alone or the combination of nivolumab and ipilimumab following concurrent chemoradiation in patients with unresectable stage III NSCLC.
What is the current status of trial NCT03285321?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 105 participants. The study started on 2017-09-15. Estimated completion is 2024-02-06.
What interventions are being tested in trial NCT03285321?
The interventions under investigation include: Nivolumab (DRUG), Ipilimumab (DRUG).
Who is sponsoring clinical trial NCT03285321?
This trial is sponsored by Greg Durm, MD, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.